Drug Profile


Alternative Names: IP 456; Panex; RP 62955

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Endo Pharmaceuticals Solutions; Indevus Pharmaceuticals; Pfizer
  • Class Anxiolytics; Naphthyridines; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Generalised anxiety disorder; Panic disorder; Premature ejaculation; Speech disorders

Most Recent Events

  • 27 Dec 2011 Discontinued - Phase-II/III for Speech disorders in USA (PO)
  • 26 Sep 2008 Pagoclone sub-licensed to Teva Pharmaceutical Industries worldwide
  • 12 Sep 2007 Discontinued - Phase-II for Generalised anxiety disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top